DE60210760T2 - Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie - Google Patents

Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie Download PDF

Info

Publication number
DE60210760T2
DE60210760T2 DE60210760T DE60210760T DE60210760T2 DE 60210760 T2 DE60210760 T2 DE 60210760T2 DE 60210760 T DE60210760 T DE 60210760T DE 60210760 T DE60210760 T DE 60210760T DE 60210760 T2 DE60210760 T2 DE 60210760T2
Authority
DE
Germany
Prior art keywords
methyl
bis
tolyl
trifluoromethyl
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210760T
Other languages
German (de)
English (en)
Other versions
DE60210760D1 (de
Inventor
Susanne Buser
P. Anthony Mountain View FORD
Torsten Hoffmann
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60210760D1 publication Critical patent/DE60210760D1/de
Publication of DE60210760T2 publication Critical patent/DE60210760T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60210760T 2001-04-23 2002-02-02 Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie Expired - Lifetime DE60210760T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
EP01109853 2001-04-23
PCT/EP2002/001085 WO2002085458A2 (en) 2001-04-23 2002-02-02 Use of nk-1 receptor antagonists against benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
DE60210760D1 DE60210760D1 (de) 2006-05-24
DE60210760T2 true DE60210760T2 (de) 2006-11-23

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210760T Expired - Lifetime DE60210760T2 (de) 2001-04-23 2002-02-02 Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie

Country Status (17)

Country Link
US (1) US20030004157A1 (OSRAM)
EP (1) EP1385577B1 (OSRAM)
JP (1) JP4146730B2 (OSRAM)
KR (1) KR100599134B1 (OSRAM)
CN (1) CN100398106C (OSRAM)
AR (1) AR035935A1 (OSRAM)
AT (1) ATE323531T1 (OSRAM)
AU (1) AU2002250876B2 (OSRAM)
BR (1) BR0209151A (OSRAM)
CA (1) CA2444395C (OSRAM)
DE (1) DE60210760T2 (OSRAM)
DK (1) DK1385577T3 (OSRAM)
ES (1) ES2261657T3 (OSRAM)
MX (1) MXPA03009720A (OSRAM)
PT (1) PT1385577E (OSRAM)
WO (1) WO2002085458A2 (OSRAM)
ZA (1) ZA200308110B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
CN100562320C (zh) * 2003-01-31 2009-11-25 弗·哈夫曼-拉罗切有限公司 2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
ATE500224T1 (de) 2004-07-06 2011-03-15 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin- derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5497633B2 (ja) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
NZ614151A (en) 2007-12-07 2015-04-24 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2231606B1 (en) 2007-12-07 2013-02-13 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
AU2010225747A1 (en) 2009-03-17 2011-11-10 Daiichi Sankyo Company,Limited Amide derivative
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
JP5806420B1 (ja) 2013-11-08 2015-11-10 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
JP7400180B2 (ja) * 2018-02-02 2023-12-19 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 非経口製剤及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
HUP0003548A3 (en) * 1997-08-06 2002-04-29 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
US6358994B1 (en) * 1997-08-06 2002-03-19 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DE60014216T2 (de) * 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
CN1503684A (zh) 2004-06-09
CN100398106C (zh) 2008-07-02
EP1385577B1 (en) 2006-04-19
JP4146730B2 (ja) 2008-09-10
CA2444395A1 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
DK1385577T3 (da) 2006-08-21
ZA200308110B (en) 2005-03-30
AR035935A1 (es) 2004-07-28
CA2444395C (en) 2010-12-21
ES2261657T3 (es) 2006-11-16
EP1385577A2 (en) 2004-02-04
US20030004157A1 (en) 2003-01-02
BR0209151A (pt) 2004-07-13
PT1385577E (pt) 2006-08-31
DE60210760D1 (de) 2006-05-24
MXPA03009720A (es) 2004-01-29
AU2002250876B2 (en) 2005-03-03
KR20040007503A (ko) 2004-01-24
KR100599134B1 (ko) 2006-07-12
WO2002085458A2 (en) 2002-10-31
WO2002085458A3 (en) 2003-10-30
ATE323531T1 (de) 2006-05-15

Similar Documents

Publication Publication Date Title
DE60210760T2 (de) Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
DE69532118T2 (de) Neue starke induktoren der terminalen differenzierung und verfahren für ihre verwendung
DE69427337T2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE69616375T2 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE69430232T2 (de) Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase
JP2004536119A (ja) 脳、脊髄又は神経損傷の処置のためのｎｋ−１レセプターアンタゴニストの使用
AU2002328837A1 (en) Use of NK-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
AU2002250876A1 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
EP0752246A2 (de) Kappa-Opiate für entzündliche Darmerkrankungen
DE69427591T2 (de) 7-(2-imidazolinylamino)quinolin-verbindungen als alpha-2 adrenorezeptor-agonisten
DE69333413T2 (de) 5-ht2-antagonisten in der behandlung venöser zustände
DE69326459T2 (de) Wirkstoffe zur behandlung von suchterkrankungen
DE69500673T2 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
DE69524780T2 (de) Verwendung von indolderivaten zur behandlung von dermatologischen krankheiten, peridhren neuropathien, arthritis, allergischen oder chronisch-obstruktiven atemwegserkrankungen, glaukom und augenentzündungen
DE69524590T2 (de) Zusammensetzung von 5htida und 5htid antagonisten
DE19953024A1 (de) Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE69630465T2 (de) Vorsorge-/heilmittel fur die komplikationen von diabetes
WO1998016224A1 (de) Pyrazolinone zur behandlung von potenzstörungen
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE60016803T2 (de) Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen
DE3873210T2 (de) Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz.
DE60218203T2 (de) Verbindungen und verfahren zur behandlung einer hyperaktiven blase
EP1605976B1 (de) Kombination von phenylcarbonsäureamiden mit blockern des ikr-kanals und deren verwendung zur behandlung von vorhofarrhythmien
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition